Sage Therapeutic Net Worth
Sage Therapeutic Net Worth Breakdown | SAGE |
Sage Therapeutic Net Worth Analysis
Sage Therapeutic's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sage Therapeutic's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sage Therapeutic's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sage Therapeutic's net worth analysis. One common approach is to calculate Sage Therapeutic's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sage Therapeutic's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sage Therapeutic's net worth. This approach calculates the present value of Sage Therapeutic's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sage Therapeutic's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sage Therapeutic's net worth. This involves comparing Sage Therapeutic's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sage Therapeutic's net worth relative to its peers.
Enterprise Value |
|
To determine if Sage Therapeutic is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sage Therapeutic's net worth research are outlined below:
| Sage Therapeutic generated a negative expected return over the last 90 days | |
| Sage Therapeutic has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 86.45 M. Net Loss for the year was (541.49 M) with loss before overhead, payroll, taxes, and interest of (319.29 M). | |
| Sage Therapeutic currently holds about 1.51 B in cash with (540.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.47, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: A Brand New Bathhouse is Open in Renton |
Sage Therapeutic uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sage Therapeutic. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sage Therapeutic's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Sage Therapeutic's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sage Therapeutic is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sage Therapeutic backward and forwards among themselves. Sage Therapeutic's institutional investor refers to the entity that pools money to purchase Sage Therapeutic's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2024-09-30 | 770.3 K | Federated Hermes Inc | 2024-09-30 | 675.3 K | D. E. Shaw & Co Lp | 2024-09-30 | 647 K | Jefferies Financial Group Inc | 2024-09-30 | 622.5 K | Citadel Advisors Llc | 2024-09-30 | 609.5 K | 683 Capital Management Llc | 2024-09-30 | 600 K | Renaissance Technologies Corp | 2024-09-30 | 513.3 K | Bank Of America Corp | 2024-06-30 | 510.9 K | Northern Trust Corp | 2024-09-30 | 494.9 K | Vanguard Group Inc | 2024-09-30 | 5.8 M | Rtw Investments, Llc | 2024-09-30 | 5.6 M |
Follow Sage Therapeutic's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 339.51 M.Market Cap |
|
Project Sage Therapeutic's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.73) | (0.76) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.68) | (0.64) |
When accessing Sage Therapeutic's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sage Therapeutic's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sage Therapeutic's profitability and make more informed investment decisions.
Please note, the presentation of Sage Therapeutic's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sage Therapeutic's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sage Therapeutic's management manipulating its earnings.
Evaluate Sage Therapeutic's management efficiency
Sage Therapeutic has return on total asset (ROA) of (0.2962) % which means that it has lost $0.2962 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4934) %, meaning that it created substantial loss on money invested by shareholders. Sage Therapeutic's management efficiency ratios could be used to measure how well Sage Therapeutic manages its routine affairs as well as how well it operates its assets and liabilities. As of December 2, 2024, Return On Tangible Assets is expected to decline to -0.64. In addition to that, Return On Capital Employed is expected to decline to -0.76. At present, Sage Therapeutic's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 7.3 M, whereas Other Current Assets are forecasted to decline to about 21.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.36 | 11.59 | |
| Tangible Book Value Per Share | 13.36 | 11.59 | |
| Enterprise Value Over EBITDA | (2.26) | (2.37) | |
| Price Book Value Ratio | 1.62 | 1.70 | |
| Enterprise Value Multiple | (2.26) | (2.37) | |
| Price Fair Value | 1.62 | 1.70 | |
| Enterprise Value | 1.2 B | 1.8 B |
At Sage Therapeutic, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 2.0962 | Revenue 106.4 M | Quarterly Revenue Growth 3.371 | Revenue Per Share 1.76 | Return On Equity (0.49) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sage Therapeutic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sage Therapeutic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sage Therapeutic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sage Therapeutic Corporate Filings
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
ASR | 17th of September 2024 Automatic Shelf Registration Statement under Rule 415 filed with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
Sage Therapeutic Earnings per Share Projection vs Actual
Sage Therapeutic Corporate Management
| Anne Esq | General VP | Profile | |
| Jim Doherty | Chief Officer | Profile | |
| Aaron MD | Medical Development | Profile | |
| Christopher Benecchi | Chief Officer | Profile | |
| Laura MD | Chief Officer | Profile | |
| Heinrich Schlieker | Senior Operations | Profile | |
| Albert Robichaud | Chief Scientific Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share 1.76 | Quarterly Revenue Growth 3.371 | Return On Assets (0.30) | Return On Equity (0.49) |
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.